Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.pnpbp.2007.05.013
DC FieldValue
dc.titleFunctional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia
dc.contributor.authorTay, J.K.X.
dc.contributor.authorTan, C.H.
dc.contributor.authorChong, S.-A.
dc.contributor.authorTan, E.-C.
dc.date.accessioned2011-09-29T05:53:55Z
dc.date.available2011-09-29T05:53:55Z
dc.date.issued2007
dc.identifier.citationTay, J.K.X., Tan, C.H., Chong, S.-A., Tan, E.-C. (2007). Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 31 (6) : 1297-1302. ScholarBank@NUS Repository. https://doi.org/10.1016/j.pnpbp.2007.05.013
dc.identifier.issn02785846
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/27218
dc.description.abstractCYP1A2 is an important inducible enzyme involved in the metabolism of antipsychotics. This study examined two functional polymorphisms in the gene as potential markers in predicting prolongation of QTc interval in patients treated with antipsychotics. QT intervals were measured by 12-lead electrocardiography (ECG) for patients with a DSM-IV diagnosis of schizophrenia. Genomic DNA extracted from venous blood were genotyped for the two polymorphisms by PCR-RFLP. Statistically significant result for CYP1A2 * 1F was noted for all patients receiving chlorpromazine equivalent doses of above 300  mg and also for a further subgroup on antipsychotics known to be CYP1A2 substrates (p = 0.007, mean QTc in ms for A/A: 395.5 ± 15.1, A/C: 425.7 ± 25.1, C/C: 427.3 ± 20.7). For CYP1A2 * 1C, there was no statistically significant association between genotypes and mean QTc interval. Overall, there was a trend of those with the C allele of the CYP1A2 * 1F polymorphism having longer QTc intervals. The results of this study suggest that the CYP1A2 * 1F polymorphism may contribute to the risk of developing prolonged QT-interval in patients who are treated with higher doses of antipsychotics. © 2007 Elsevier Inc. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.pnpbp.2007.05.013
dc.sourceScopus
dc.subjectAntipsychotics
dc.subjectCYP1A2 gene
dc.subjectGenetic polymorphisms
dc.subjectHaplotype analysis
dc.subjectQTc interval
dc.typeArticle
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.1016/j.pnpbp.2007.05.013
dc.description.sourcetitleProgress in Neuro-Psychopharmacology and Biological Psychiatry
dc.description.volume31
dc.description.issue6
dc.description.page1297-1302
dc.identifier.isiut000249187300021
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

28
checked on Feb 17, 2020

WEB OF SCIENCETM
Citations

23
checked on Feb 17, 2020

Page view(s)

268
checked on Feb 5, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.